Skip to main content

Loading market data...

CRL

Charles River Laboratories International, Inc.

NYSE • United states

$315.45

+$15.43

(+5.14%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Charles River Laboratories International, Inc. (CRL)

Unavailable

Quotes may be delayed

$15.06B

Market Cap

1,272,223

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Charles River Laboratories International, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 251 BALLARDVALE ST, WILMINGTON, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

24 Sep 2026

Charles River Laboratories International, Inc. reported Regulation FD disclosure

Charles River Laboratories International, Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.

8 Sep 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..

6 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..

5 Aug 2026

Charles River Laboratories International, Inc. filed Form 10-Q

Charles River Laboratories International, Inc. submitted Form 10-Q to the SEC for the period ending Jun 27, 2026.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$192.03M

Total assets (USD)$7.53B

Total liabilities (USD)$4.64B

Shareholders' equity (USD)$2.84B

Long-term debt (USD)$1.63B

Debt due within a year (USD)$5.46M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 27 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$1.00B	$119.89M	−$1.48M	−$0.03	10-Q · 5 Aug 2026
Q1 2026	$995.83M	$119.90M	−$14.84M	−$0.30	10-Q · 7 May 2026
Q4 2025	$994.23M	−$283.44M	−$276.56M	Unavailable	10-K · 18 Feb 2026
Q3 2025	$1.00B	$133.80M	$54.42M	$1.10	10-Q · 5 Nov 2025
Q2 2025	$1.03B	$100.13M	$52.33M	$1.06	10-Q · 6 Aug 2025
Q1 2025	$984.17M	$74.67M	$25.47M	$0.50	10-Q · 7 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $329.85

4.6% upside potential

📈

Strong Buy

Unavailable

👍

Buy

13

⏸️

Hold

1

📉

Sell

0

14 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 00:48 UTC Targets range 295.00–357.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

5

Oct 2026

Parisotto Shannon M

CEVP, Disc & Safety Assessment

Option exercise

$208.44 per share

981 shares

5

Oct 2026

Parisotto Shannon M

CEVP, Disc & Safety Assessment

Open-market sale

$308.44 per share

981 shares

30

Sep 2026

Coleman Glenn

EVP & Chief Financial Officer

Open-market purchase

$297.43 per share

10 shares

25

Aug 2026

FOSTER JAMES C

Director

Option exercise

$199.42 per share

33,561 shares

25

Aug 2026

FOSTER JAMES C

Director

Open-market sale

$300.00 per share

33,561 shares

19

Aug 2026

Girshick Birgit

Director, Chief Executive Officer

Gift

Unavailable per share

528 shares

19

Aug 2026

Parisotto Shannon M

CEVP, Disc & Safety Assessment

Option exercise

$194.12 per share

2,039 shares

19

Aug 2026

Parisotto Shannon M

CEVP, Disc & Safety Assessment

Open-market sale

$294.12 per share

2,039 shares

18

Aug 2026

Andrews Nancy C

Director

Option exercise

$164.30 per share

573 shares

18

Aug 2026

Andrews Nancy C

Director

Open-market sale

$285.24 per share

573 shares

Top Shareholders

Vanguard Group Inc

5,887,175 shares

0.812% change

12/31/2025

Fmr Llc

4,239,752 shares

22.669% change

6/30/2026

Blackrock, Inc.

3,798,560 shares

-1.569% change

6/30/2026

Vanguard Capital Management Llc

3,149,288 shares

-1.652% change

6/30/2026

Invesco Ltd.

2,984,785 shares

24.509% change

6/30/2026

Harris Associates L P

2,241,144 shares

4.08% change

6/30/2026

Vanguard Portfolio Management Llc

2,210,979 shares

-3.647% change

6/30/2026

Allspring Global Investments Holdings, Llc

1,905,247 shares

-4.418% change

6/30/2026

State Street Corp

1,864,284 shares

-0.498% change

6/30/2026

Dimensional Fund Advisors Lp

1,648,450 shares

-0.244% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 00:48 UTC· 1 day ago

Research coverage and investment tools

Charles River Laboratories International, Inc. (CRL) is a stock listed on the New York Stock Exchange in the United States, in the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch). Its last price was US$315.45 on 20 Oct 2026. That is 90% of the way from its 52-week low of US$146.20 to its 52-week high of US$333.30. Its market capitalisation was US$15.06 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$1.00B	$119.89M	−$1.48M	−$0.03	—	11.9%	—	10-Q · 5 Aug 2026 (opens in a new tab)
Q1 2026	$995.83M	$119.90M	−$14.84M	−$0.30	—	12.0%	—	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$994.23M	−$283.44M	−$276.56M	Unavailable	—	-28.5%	—	10-K · 18 Feb 2026 (opens in a new tab)
Q3 2025	$1.00B	$133.80M	$54.42M	$1.10	—	13.3%	—	10-Q · 5 Nov 2025 (opens in a new tab)
Q2 2025	$1.03B	$100.13M	$52.33M	$1.06	—	9.7%	—	10-Q · 6 Aug 2025 (opens in a new tab)
Q1 2025	$984.17M	$74.67M	$25.47M	$0.50	—	7.6%	—	10-Q · 7 May 2025 (opens in a new tab)

Cash and equivalents: $192.03M
Total assets: $7.53B
Total liabilities: $4.64B
Shareholders' equity: $2.84B
Long-term debt: $1.63B
Debt due within a year: $5.46M

8-K · 24 Sep 2026

Charles River Laboratories International, Inc. reported Regulation FD disclosure (opens in a new tab)

Charles River Laboratories International, Inc. filed an 8-K covering Regulation FD disclosure, supporting financial statements or exhibits.
SCHEDULE 13G/A · 8 Sep 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..
SCHEDULE 13G · 13 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..
SCHEDULE 13G/A · 6 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Charles River Laboratories International, Inc..
10-Q · 5 Aug 2026

Charles River Laboratories International, Inc. filed Form 10-Q (opens in a new tab)

Charles River Laboratories International, Inc. submitted Form 10-Q to the SEC for the period ending Jun 27, 2026.

Insider	Date	Transaction	Shares	Average price	Filing
Parisotto Shannon M CEVP, Disc & Safety Assessment	5 Oct 2026	Option exercise (M)	+981	$208.44	Form 4 (opens in a new tab)
Parisotto Shannon M CEVP, Disc & Safety Assessment	5 Oct 2026	Open-market sale (S)	−981	$308.44	Form 4 (opens in a new tab)
Coleman Glenn EVP & Chief Financial Officer	30 Sep 2026	Open-market purchase (P)	+10	$297.43	Form 4 (opens in a new tab)
FOSTER JAMES C Director	25 Aug 2026	Option exercise (M)	+33,561	$199.42	Form 4 (opens in a new tab)
FOSTER JAMES C Director	25 Aug 2026	Open-market sale (S)	−33,561	$300.00	Form 4 (opens in a new tab)
Girshick Birgit Director, Chief Executive Officer	19 Aug 2026	Gift (G)	−528	—	Form 4 (opens in a new tab)
Parisotto Shannon M CEVP, Disc & Safety Assessment	19 Aug 2026	Option exercise (M)	+2,039	$194.12	Form 4 (opens in a new tab)
Parisotto Shannon M CEVP, Disc & Safety Assessment	19 Aug 2026	Open-market sale (S)	−2,039	$294.12	Form 4 (opens in a new tab)
Andrews Nancy C Director	18 Aug 2026	Option exercise (M)	+573	$164.30	Form 4 (opens in a new tab)
Andrews Nancy C Director	18 Aug 2026	Open-market sale (S)	−573	$285.24	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	5,887,175	0.812%
Fmr Llc	6/30/2026	4,239,752	22.669%
Blackrock, Inc.	6/30/2026	3,798,560	-1.569%
Vanguard Capital Management Llc	6/30/2026	3,149,288	-1.652%
Invesco Ltd.	6/30/2026	2,984,785	24.509%
Harris Associates L P	6/30/2026	2,241,144	4.08%
Vanguard Portfolio Management Llc	6/30/2026	2,210,979	-3.647%
Allspring Global Investments Holdings, Llc	6/30/2026	1,905,247	-4.418%
State Street Corp	6/30/2026	1,864,284	-0.498%
Dimensional Fund Advisors Lp	6/30/2026	1,648,450	-0.244%

Previous close: 300.02 USD
Day range: 304.00 – 317.56 USD
52-week range: 146.20 – 333.30 USD
Volume: 1,272,223
Market cap: $15.06B
Average volume: 349,040
EPS (FY 2025, diluted): −2.91 USD
Shares outstanding: 47.74M
Beta (5Y monthly): 1.38

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:21 UTC· 53 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for CRL yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.